The study compared the new drug zoliflodacin with the combination of ceftriaxone 500 mg intramuscularly + azithromycin 1 g orally in patients with uncomplicated urogenital gonorrhea.[1] Participants were randomized 2:1 to a single dose of zoliflodazine 3 g orally or standard combination therapy.[1] The primary objective was the microbiological eradication of Neisseria gonorrhoeae in the urogenital tract when checked on day 6 ± 2 days.[1] Microbiological cure was achieved by 460 of 506 patients (90.9%, 95% CI 88.1–93.3) in the zoliflodazine group and 229 of 238 patients (96.2%, 95% CI 92.9–98.3) in the comparison group.[1] The difference was a priori statistically assessed as non-inferiority, meaning that zoliflodacin was non-inferior to standard treatment within the established 12% limit.[1] The safety profile of zoliflodazine was similar to that of the combination of ceftriaxone and azithromycin.[1] The results show that a single oral dose of zoliflodazine is an effective treatment option for uncomplicated urogenital gonorrhea.[1]